Position in EXEL
as of Jun 30, 2026
· filed Jul 16, 2026
Position Value
$3,152,678
+$2,146,608 QoQ
Shares Held
57,943
+147.0% QoQ
Ownership
0.023%
of shares outstanding
% of Portfolio
0.26%
of 13F equity value
Holder Rank
#20
of 154 holders
Holding Since
Dec 2022
5 quarters on record
Voting authority
Sole 0%
Shared 0%
None 100%
Common Shares in EXEL Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026Linden Thomas Advisory Services, LLC holds $36,440,714 across 14 Biotechnology names. EXEL ranks #5 (8.7% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | CPRX |
Catalyst Pharmaceuticals, Inc.
|
176,004 | $5,531,805 | |
| 2 | INCY |
Incyte Corp
|
46,507 | $5,272,033 | |
| 3 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
8,103 | $4,025,003 | |
| 4 | REGN |
Regeneron Pharmaceuticals, Inc.
|
5,106 | $3,183,795 | |
| 5 | EXEL |
Exelixis, Inc.
This page
|
57,943 | $3,152,678 | |
| 6 | LGND |
Ligand Pharmaceuticals Inc
|
9,935 | $3,140,354 | |
| 7 | CORT |
Corcept Therapeutics Inc
|
34,641 | $3,012,034 | |
| 8 | VCEL |
Vericel Corp
|
56,051 | $2,493,708 |
All Filings in EXEL
Export CSV
5 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $3,152,678 | 57,943 | Shares | Sole | 2026-07-16 | |
| 2026-03-31 | $1,006,070 | 23,457 | Shares | Sole | 2026-04-10 | |
| 2023-06-30 | $1,174,003 | 61,434 | Shares | Sole | 2023-07-27 | |
| 2023-03-31 | $1,177,216 | 60,650 | Shares | Sole | 2023-04-25 | |
| 2022-12-31 | $916,220 | 57,121 | Shares | Sole | 2023-02-17 | |
| No filing history on record for this holder in this stock. | ||||||